摘要
非创伤性股骨头坏死(nontraumatic osteonecrosis of the femoral head,NONFH)是好发于青壮年人群且致残率极高的骨科常见疾病,其发病机制尚未完全确定。纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor-1,PAI-1)作为一种重要的生理调节因子,在NONFH患者的血栓形成、纤维溶解能力减弱、血管生成减少、内皮损伤增加、骨细胞状态异常改变等病理活动中均起到重要作用。NONFH患者血清中的PAI-1水平存在特异性升高,这种改变可以作为无创性生物标志物用于NONFH的诊断。本文全面综述PAI-1与NONFH的关系以及PAI-1抑制剂在NONFH治疗上的潜在应用,提出PAI-1可以作为重要的NONFH治疗靶点,总结了多种PAI-1抑制剂的重要临床和科研价值。
Nontraumatic osteonecrosis of the femoral head(NONFH)is a highly disabling orthopedic disease,which occurs frequently in young and middle-aged people,but its pathogenesis has not been fully determined.Plasminogen activator inhibitor-1(PAI-1),an important regulator of hypofibrinolysis,has closely been associated with NONFH’s pathological activity,such as thrombosis,decreased fibrinolysis,descended angiogenesis,increased endothelial damage,abnormal changes of bone cells.Specific upregulated PAI-1 can be identified in the serum of patients with NONFH,which can be used as a non-invasive biomarker for the diagnosis of NONFH.In this paper,the relationship between PAI-1 and NONFH and the potential application of PAI-1 inhibitors in the treatment of NONFH were reviewed.PAI-1 has the potential to be a diagnostic marker for NONFH.The important clinical and scientific value of PAI-1 inhibitors were summarized.
作者
王奕凯
李璐
于炜婷
赵德伟
WANG Yikai;LI Lu;YU Weiting;ZHAO Dewei(Department of Orthopaedics,Zhongshan Hospital of Dalian University,Dalian 116001,Liaoning;National-Local Joint Engineering Laboratory for the Development of Orthopedic Implant Materials,Zhongshan Hospital of Dalian University,Dalian 116001,Liaoning;Medical College of Dalian University,Dalian 116001,Liaoning,China)
出处
《中华骨与关节外科杂志》
2020年第10期874-880,共7页
Chinese Journal of Bone and Joint Surgery
作者简介
共同第一作者:李璐;通信作者:赵德伟,E-mail:zhaodewei2000@163.com
